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Bronchodilator response (BDR) is conventionally defined as a greater than 12% and greater than 200ml 34 
increase from baseline in forced expiratory volume in 1 second (FEV1) measured using spirometry.1 Forced 35 
expiratory flow between 25-75% of forced vital capacity (FEF25-75) is thought to reflect volume dependent 36 
closure of the small airways. Impulse oscillometry (IOS) is an effort-independent forced oscillation 37 
technique (FOT) using sound waves superimposed on normal tidal breathing, requiring minimal patient 38 
cooperation and is therefore more physiological. Persistent BDR is associated with worse asthma control 39 
albeit lung function is often disconnected from patient reported symptoms.2,3 Due to the ease of 40 
performing IOS measurements, IOS BDR threshold had been widely assessed in pediatric pulmonology.4 41 
However, IOS BDR thresholds in adults are still not clearly defined. We therefore sought to determine the 42 
difference between spirometry and IOS BDR in patients with well and poorly controlled asthma. 43 
Retrospectively, we evaluated 57 patients with an established diagnosis of persistent asthma who 44 
attended the Scottish Centre for Respiratory Research (Dundee, UK) for screening into clinical trials. 45 
Asthma control questionnaire (ACQ-6), fractional exhaled nitric oxide (FeNO) and lung function tests 46 
including spirometry (Micromedical, Chatham, United Kingdom) and IOS (Jaeger MasterScreen, 47 
Carefusion Technologies) were performed pre and post albuterol 400µg in triplicate according to ERS 48 
guidelines, with IOS always performed first.5  Consents were obtained from all patients for access to their 49 
screening data. 50 
We used an ACQ-6 cut point of 1.0 to define poor asthma control.6 A comparison was made according to 51 
pre-defined cut points for IOS BDR values: area under the reactance curve (AX) <35% vs ≥35%; reactance 52 
at 5Hz (X5) <15% vs ≥15%; resonance frequency (Fres) <15% vs ≥15% and resistance at 5Hz (R5) <15% vs 53 
≥15%. The comparisons were conducted using Independent Student’s T test with alpha error set at 0.05 54 
(2 tailed). Receiver operator characteristic (ROC) curves were plotted to assess sensitivity and specificity 55 
of IOS and spirometry % BDR for detecting poor asthma control.      56 
The mean age was 51 years; FEV1 79% predicted; AX 1.35 kPa/L; R5 0.41 kPa/L/s; R20 0.37 kPa/L/s; R5-57 
R20 0.12 kPa/L/s; ACQ-6 1.38 and FeNO 38 ppb. Mean inhaled corticosteroid (beclomethasone 58 
equivalent) dose was 670µg; and 68% were taking LABA; 11% LAMA; 25% LTRA; and 4% theophylline.  59 
Using an ACQ-6 <1 and ≥1 to compare well and poorly controlled asthma, there were significant 60 
differences in % BDR with FEV1, AX, X5, Fres and R5 (Table 1). In the subgroup with a preserved FEV1 of 61 
≥80% (n=30), % BDR for AX, X5, R5 and FEF25-75 were significantly higher in poorly controlled asthma. In 62 
the cohort with no spirometry evidence of BDR as represented by a FEV1 BDR <12% and <200ml (n=37), 63 
AX, X5 and R5 were significantly higher in those with poorly controlled asthma. FeNO was also significantly 64 
higher in the poorly controlled group.  65 
Asthma control (as mean ACQ-6) was significantly worse comparing % BDR for AX <35% vs ≥35%: 0.92 vs 66 
1.79 (95%CI for difference 0.34, 1.40;p<0.01); X5 <15% vs ≥15%: 0.77 vs 1.73 (CI 0.48, 1.44;p<0.001); Fres 67 
<15% vs ≥15%: 0.93 vs 1.76 (CI 0.31, 1.35;p<0.01); R5 <15% vs ≥15%: 0.90 vs 1.79 (CI 0.37, 1.40;p<0.01); 68 
and FEV1 <12% vs ≥12%: 1.22 vs 2.22 (CI 0.26, 1.75;p<0.01). 69 
In patients with preserved FEV1, ACQ-6 were also significantly higher comparing % BDR for: AX at a cut-70 
point of 35%: 0.73 vs 1.60 (CI 0.25, 1.49;p<0.01); X5 15%: 0.71 vs 1.56(CI 0.26, 1.44;p<0.01); Fres 15%: 71 
0.84 vs 1.52(CI 0.07, 1.29;p<0.05) and R5 15%: 0.81 vs 1.56(CI 0.16, 1.35;p<0.05). These differences in 72 
ACQ-6 all exceeded the minimal clinical important difference of 0.5.     73 
ROC curve analysis for predicting poor asthma control with IOS % BDR, namely AX, X5, Fres and R5, 74 
demonstrated fair accuracy with AUC between 0.70-0.80 (Table 2). Poor asthma control was detected 75 
with a BDR of 35% for AX; 14% for X5; 15% for Fres; and 15% for R5. The corresponding sensitivity and 76 
specificity values are shown in Table 2. The AUC were 0.69(CI 0.55, 0.83;p<0.05) and 0.66(CI 0.51, 77 
0.80;p<0.05), sensitivity: 23% and 45%, specificity: 96% and 77% for FEV1 12% and 200ml BDR respectively.  78 
Our results demonstrate that IOS % BDR for airway reactance (AX, X5), resonance frequency and 79 
resistance at 5Hz were all associated with poor asthma control. This was also observed with FEV1 but not 80 
FEF25-75 in all patients, while in those patients with preserved FEV1 poor control was associated with 81 
increased % BDR for FEF25-75. This is consistent with a previous study comparing relative 82 
bronchoconstrictor and bronchodilator response using IOS and spirometry in asthma patients.7 Another 83 
study also reported similar findings in asthma with the relative mean percentage change in response to 84 
albuterol 400µg being 6% and 34% for FEV1 and R5 respectively.8  85 
Notably the IOS % BDR in the subgroup of asthma patients with preserved FEV1 was significantly higher in 86 
the poorly controlled group. This perhaps reflects that alterations in small airway geometry are more 87 
closely related to asthma control. The persistently higher FeNO in the poorly controlled group mirrors 88 
underlying type 2 inflammation and is associated with a greater degree of IOS BDR.   89 
A recent study also concluded that the reactance components of FOT were more sensitive than spirometry 90 
in detecting poor asthma control.9 However, they used reference values for FOT BDR derived from healthy 91 
subjects which would not be applicable to asthma patients where a greater reversibility would be 92 
expected due to alterations in resting bronchomotor tone and airway geometry.   93 
We recognize the main limitation of our study as being retrospective and cross-sectional with a relatively 94 
small sample size. However, our findings are consistent with previous studies with larger sample sizes and 95 
controlled trials.7, 8 Our study may have clinical implications suggesting that effort-independent IOS may 96 
provide complimentary information on BDR in patients with poorly controlled asthma, especially in those 97 
with preserved FEV1. 98 
In conclusion, bronchodilator response using IOS measurements is associated with poor asthma control. 99 
IOS is more sensitive than spirometry in detecting bronchodilator response in poorly controlled asthma 100 
especially in those patients with a preserved FEV1.  101 
 102 
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Table 1 149 
 Overall FEV1 ≥ 80% FEV1 BDR <12% and <200ml 
 ACQ <1 ACQ≥1 ACQ <1 ACQ≥1 ACQ <1 ACQ≥1 
FEV1 % BDR 5 8 5 6 4 4 
 *(1, 6) (-4, 1) (-3, 1) 
FEF25-75 % BDR 12 17 9 22 11 16 
 (-12, 2) **(-21, -4) (-13, 3) 
AX % BDR 26 49 22 45 22 43 
 ***(11, 34) *(5, 40) **(6, 35) 
X5 % BDR 12 28 7 28 9 25 
 ***(8, 25) **(9, 33) **(4, 26) 
Fres % BDR 14 22 13 19 13 19 
 *(1, 14) (-4, 15) (-14, 1) 
R5 % BDR 10 19 8 18 9 18 
 **(4, 14) **(4, 17) **(3, 15) 
R20 % BDR 10 12 7 13 8 12 
 (-2, 7) (0.26, 11) (-10, 2) 
R5-R20 % BDR -27 39 23 34 26 31 
 (-6, 30) (-15, 38) (-28, 18) 
FeNO ppb 25 49 22 52 24 46 
 **(10, 37) *(8, 52) *(3, 41) 
ACQ = Asthma control questionnaire-6, BDR = bronchodilator response, FEV1 = forced expiratory volume in 1st second, 
FEF25-75 = forced expiratory volume at 25-75% of forced vital capacity, AX = area under the reactance curve, X5 = 
reactance at 5Hz, Fres = resonance frequency, R5 = resistance at 5Hz, R20 = resistance at 20Hz, R5-R20 = difference in 
resistance at 5 and 20 Hz, FeNO = fractional exhaled nitric oxide. Values are presented as mean (95% CI for difference).  
* p<0.05, ** p<0.01, ***p<0.001 
 150 
 151 
Table 2 152 
 % BDR % sensitivity % specificity AUC (95% CI) 
R5 15 77 73 0.77 (0.63, 0.91)** 
AX 35 77 73   0.78 (0.65, 0.91)*** 
X5 14 84 61 0.76 (0.63, 0.89)** 
Fres 15 71 65 0.71 (0.57, 0.86)** 
BDR = bronchodilator response, AX = area under the reactance curve, X5 = reactance at 5Hz, Fres 
= resonance frequency, R5 = resistance at 5Hz, AUC = area under the curve, CI = confidence 
interval. * p<0.05, ** p<0.01, ***p<0.001. 
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